Industry Summits
U.S. reform a future boost for drugmakers, others
NEW YORK (Reuters) - Could U.S. healthcare reform improve the industry's profit prognosis? Full Article
Hassan sees Merck retaining Remicade
NEW YORK (Reuters) - Fred Hassan, former head of Schering-Plough Corp, said Merck & Co is likely to prevail over Johnson & Johnson in its battle to retain overseas rights to the blockbuster arthritis drug Remicade. Full Article
FDA chief defends H1N1 vaccine supply
NEW YORK (Reuters) - The head of the U.S. Food and Drug Administration defended the agency's decision not to use an additive that could have stretched swine flu vaccine supplies, adding that doses should be coming more regularly. Full Article | Video
Sign up here to be alerted via email about top news broken from these exclusive interviews, as well as the list of guests for upcoming Reuters Summits.
Drugmakers hopeful of better FDA climate
NEW YORK (Reuters) - Drugmakers who have complained for years about caution and unpredictability at the U.S. Food and Drug Administration see signs the climate for reviewing new medicines may be improving. Full Article
Glaxo sees recurring pandemic flu business
NEW YORK (Reuters) - Sales of flu treatments due to the H1N1 swine flu pandemic may be sustainable beyond the current winter season, as governments around the world overhaul their long-term strategy on stockpiles. Full Article
FDA head to speed reviews, visit China
NEW YORK (Reuters) - The U.S. Food and Drug Administration is working to increase the speed of drug reviews and clean up problems in the division that oversees medical devices, the agency's commissioner said on Thursday. Full Article
Glaxo CEO sees little risk to margins
NEW YORK (Reuters) - GlaxoSmithKline Plc does not expect profit margins to slip substantially, despite an aggressive drive to diversify into areas like emerging markets and consumer health, its chief executive said on Thursday. Full Article
FDA seeks to streamline device unit
NEW YORK (Reuters) - The new head of the U.S. Food and Drug Administration said she is working to clean up the agency's troubled device unit, including a review of how it approves medical devices. Full Article
Glaxo sees Benlysta as "very major" opportunity
NEW YORK (Reuters) - GlaxoSmithKline Plc said on Thursday it expects its experimental lupus drug Benlysta to be a "very major" product and contribute meaningfully to the company's bottom line. Full Article
Medical device prices in crosshairs of reform
NEW YORK (Reuters) - Cash-strapped hospitals are stepping up pressure on the prices of medical devices -- from knee replacements to diagnostic tests and surgical systems -- as momentum builds toward U.S. healthcare reform. Full Article
More Health News
Speakers
What are Summits?
Reuters Summits are your direct link to top business leaders, investors and regulators. Our journalists interview heavyweights in a particular industry, spin out hard-hitting breaking news and sharp analysis that can often move markets. If you want to understand what the insiders are thinking, look for Reuters Summits. Launch Full Video
| Global Media | Nov 30 - Dec 3 | New York, London, Asia |
| Investment Outlook | Dec 8 - 10 | New York, London |
| Aerospace and Defense | Dec 14 - 16 | Washington, DC |
